Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma

Fig. 1

The clonoSEQ Assay Processg: DNA is extracted from the patient sample, and the CDR3 regions of B- and T-cell receptors are subject to multiplexPCR to amplify their unique VDJ or VJ sequences. Amplified DNA undergoes a second round of PCR to add index sequences to prepare for NGS, which is performed via synthesis. The resulting sequences are processed by bioinformatics software to ensure accuracy of results

Back to article page